Study identifier:NIS-GKR-DUM-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Non-interventional, cross-sectional, multi-center study to establish The clinical significance of minimal change in reflux esophagitis based on the Gastroesophageal Reflux Disease Questionnaire (GerdQ)
Gastroesophageal Reflux Disease
-
No
-
All
1550
Observational
20 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to define the endoscopic findings of minimal change that is significant to clinical significant reflux esophagitis. Through this, the investigators want to estimate the applicability of minimal change findings of reflux esophagitis to the clinic.
Location
Location
Busan, Republic of Korea
Location
Daegu, Republic of Korea
Location
Daejun, Republic of Korea
Location
Kwangju, Republic of Korea
Location
Seoul, Republic of Korea
Location
Sungman, Republic of Korea
Location
Suwon, Republic of Korea
Arms | Assigned Interventions |
---|---|
1 Reflux esophageal minimal change in the endoscopic finding | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.